Nowadays we have a wide range of medicines and treatments. But these unfortunately cost money. In more economically developed countries, you pay for your health whilst you're healthy as in health insurance unless the government provides a free healthcare service.

Whilst a person is ill, they will have to use their health insurance if necessary in order to get their medical bills paid. If the patient are getting a free treatment. They will still have to find a way to get their bills paid if they are too sick to turn up to work. This is the reason why patients should have payment protection or payment insurance on all their bills, which not everyone can afford. If a person has no medical insurance and they suffer a fatal illness which they have to get operated on in order to save their life, they will become homeless and lose all their possessions due to the collateral being placed on the house.

Medicine is very expensive and we are exceptionally lucky that we have illnesses, and mental disorders which can be treated with a free healthcare service which we sometimes take for granted, whether that is by drugs, radiation, surgery or anything else.

Medicines are patented, tweaked to extend the exclusive rights and then licensed to other companies to rebrand and resell to keep the rights to escape the negative effects when the term of patent wears off. A good example of this is when Novatris challenged the Chennai high court over patent laws in India.
The bottom line of medicine is that the drug companies worldwide are making millions of pounds in profit. Should this be allowed? Should some of these millions be used to buy free healthcare? Surely these corporations won't mind as a couple million won't hurt.

But the sad fact is that without this profit, drug companies have no incentive to spend years researching into drugs. That price you pay is the price you pay for health. Poorer countries cannot always afford that price, so people in those countries end up dying.

Such outcomes prevent and discourage the distribution and investment in new and upcoming medicines in less economically developed countries (LEDCs).